- America’s STD Rate at Record High Again: CDC
- AHA News: 5 Things to Know This Earth Day About How the Environment Affects Health
- Health Highlights: April 14, 2021
- Many Kids Who Develop Severe COVID-Linked Syndrome Have Neurologic Symptoms
- Cloth Masks Do Make Workouts a Bit Tougher, Study Finds
- No Rise in Global Suicide Rate in First Months of Pandemic
- Teen Tanning Bed Ban Would Prevent Thousands of U.S. Melanoma Cases
- Research Shows Links Between Gum Disease and Alzheimer’s
- J&J Vaccine ‘Pause’ Is Not Mandate Against the Shot, FDA Says
- CBD or THC? Cannabis Product Labels Often Mislead, Study Finds
Tretten Approved for Genetic Clotting Disorder
Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
People with the genetic disorder do not make enough Factor XIII, a blood component that promotes clotting. Tretten, a human recombinant produced in yeast cells, makes up for this deficiency, which could otherwise be life threatening, the FDA said Monday in a news release.
Tretten was evaluated in a clinical study of 77 people with the disorder. Administered monthly, it was effective in preventing bleeding in 90 percent of recipients. Side effects included headache, extremity pain and pain at the injection site. No study participant developed abnormal clotting, the FDA said.
The product was developed and is produced by Novo Nordisk, based in Denmark.
More information
To learn more about this disorder, visit the National Hemophilia Foundation.
Source: HealthDay
